Results 141 to 150 of about 364,439 (227)

High measles and rubella vaccine coverage and seroprevalence among Zambian children participating in a measles and rubella supplementary immunization activity. [PDF]

PLOS Glob Public Health
Prosperi C, Truelove S, Carcelen AC, Chongwe G, Mwansa FD, Ndubani P, Simulundu E, Bwalya IC, Hamahuwa M, Kapungu K, Matakala KH, Musukwa G, Mutale I, Betha E, Chaavwa N, Kampamba L, Matoba J, Munachoonga P, Mufwambi W, Situtu K, Thuma PE, Sakala C, Kayeye P, Winter AK, Ferrari MJ, Moss WJ, Mutembo S.   +26 more
europepmc   +1 more source

Corrigendum to "Examination of scenarios introducing rubella vaccine in the Democratic Republic of the Congo" [Vaccine: X 9 (2021) 100127]. [PDF]

Vaccine X, 2022
Cheng A, Frey K, Mwamba GN, McCarthy KA, Hoff NA, Rimoin AW.   +5 more
europepmc   +1 more source

Measles & Rubella Initiative 2017

The Measles & Rubella Initiative is a global partnership committed to ensuring no child dies from measles or is born with congenital rubella syndrome.Publication date from document properties.measles-rubella-fact-sheet ...

core  

Estimated Current and Future Congenital Rubella Syndrome Incidence with and Without Rubella Vaccine Introduction - 19 Countries, 2019-2055. [PDF]

MMWR Morb Mortal Wkly Rep
Lebo E, Vynnycky E, Alexander JP, Ferrari MJ, Winter AK, Frey K, Papadopoulos T, Grant GB, O'Connor P, Reef SE, Crowcroft NS, Zimmerman LA.   +11 more
europepmc   +1 more source

Prediction of Specific Antibody- and Cell-Mediated Responses Using Baseline Immune Status Parameters of Individuals Received Measles-Mumps-Rubella Vaccine. [PDF]

Viruses, 2023
Toptygina A, Grebennikov D, Bocharov G.
europepmc   +1 more source

Comparative Immunogenicity and Safety of Measles-Mumps-Rubella Vaccine When Administered Using Needle Free Injection System to That with Conventional Needle-Syringe in India: A Randomized, Parallel Group Study. [PDF]

Med Devices (Auckl)
Ratta BS, Naik A, Mutha S.
europepmc   +1 more source

Examination of scenarios introducing rubella vaccine in the Democratic Republic of the Congo. [PDF]

Vaccine X, 2021
Cheng A, Frey K, Mwamba GN, McCarthy KA, Hoff NA, Rimoin AW.   +5 more
europepmc   +1 more source

Immunogenicity and Safety Results of a Randomized, Three-Arm, Phase IV Clinical Trial of Concomitant Administration of Typhoid Vi Conjugate Vaccine with Measles and Rubella Vaccine in Healthy Infants. [PDF]

Viruses
Rao SN, Ambike D, Patil M, Mankar SV, Verma N, Hanumante N, Sarangi L, Mitra M, Preeti G, Deshmukh BJ, Nanoti G, Faridi MMA, Daultani P, Mittal R, Maithal K, Kansagra K, Parmar DV, Kunnathamman R, Elaiyaraja M, Dutta T, Mahajan M, Desai S.   +21 more
europepmc   +1 more source

Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial. [PDF]

Vaccines (Basel), 2023
Baker B, Bermingham IM, Leelasena I, Hickling J, Young PR, Muller DA, Forster AH.   +6 more
europepmc   +1 more source

Measles, mumps and rubella vaccine and heterologous immunity: a way out of the COVID-19 crisis? [PDF]

Sudan J Paediatr, 2022
Shrivastava J, Narang M, Gomber S.
europepmc   +1 more source